Given that CRC cells with low LPCAT2 expression showed more malignancy than those with high LPCAT2 expression, we sought to examine whether inhibition of PRMT1 and SLC7A11 would have a favorable therapeutic effect on LPCAT2 low expression CRC cells. Here, PRMT1 is linked to colorectal carcinoma.